Pharming Group N.V. PHAR
12.90 USD -0.51 (-3.77%)
Nov 12, 2026, 9:59 AM EST
12.90 Day range 13.05
9.11 52-week range 21.34
- YTD
- -27.02%
- 1 year
- -24.81%
News
globenewswire.com Pharming to participate in fireside chat at Jefferies Global Healthcare Conference in London Pharming to participate in fireside chat at Jefferies Global Healthcare Conference in London on Wednesday Nov. 18 at 9:30 am GMT. Webcast will be available
benzinga.com Pharming Receives U.K. Approval For Joenja In Children Aged 4 To 11 With APDS, Supported By Pediatric Clinical Program Data; Marks Step In Expansion Across Age Groups And Markets Approval extends existing U.K. indication for Joenja to eligible children aged 4 to 11 who weigh at least 27 kgJoenja is expected to become available to patients covered by the expanded indication in…
globenewswire.com MHRA approves Pharming's Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K. MHRA approves Pharming's Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K. Approval extends existing U.K. indication.
benzinga.com Canaccord Genuity Maintains Buy on Pharming, Raises Price Target to $41 Canaccord Genuity analyst Whitney Ijem maintains Pharming (NASDAQ:PHAR) with a Buy and raises the price target from $38 to $41.
benzinga.com Pharming Q3 2026 Earnings Call Transcript Pharming (NASDAQ:PHAR) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Pharming Affirms FY2026 Sales Guidance of $380.000M-$390.000M vs $383.333M Est Pharming (NASDAQ:PHAR) affirms FY2026 sales outlook from $380.000 million-$390.000 million to $380.000 million-$390.000 million vs $383.333 million estimate.
benzinga.com Pharming Q3 EPS $0.30 Beats $0.02 Estimate, Sales $117.600M Miss $117.733M Estimate Pharming (NASDAQ:PHAR) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.02 by 1400 percent. This is a 200 percent increase over earnings of $0.10 per…
benzinga.com Selective Insurance, Crown Castle, UWM Holdings And Other Big Stocks Moving Higher On Friday U.S. stocks fell Friday, but Selective Insurance surged after beating EPS estimates, approving a $200M buyback and raising its dividend.
benzinga.com Crude Oil Moves Higher; Lockheed Martin Posts Upbeat Earnings U.S. stocks fell, led by a 2% Nasdaq drop; Lockheed Martin beat estimates and raised guidance. Oil rose, while global markets and metals declined.
benzinga.com Healthcare Services Posts Upbeat Q3 Earnings, Joins Pool, Spotify And Other Big Stocks Moving Higher On Thursday U.S. stocks fell, but Healthcare Services Group jumped 8.2% on an earnings beat. Biohaven led gainers, surging 30.5% after FDA news.- benzinga.com Pharming Narrows FY2026 Sales Guidance from $375.000M-$395.000M to $380.000M-$390.000M vs $389.333M Est Pharming (NASDAQ:PHAR) narrows FY2026 sales outlook from $375.000 million-$395.000 million to $380.000 million-$390.000 million vs $389.333 million estimate.
- benzinga.com Pharming Reports Preliminary Q3 Revenues $117.6M, Up 21% YoY; Operating Expenses $74.6M Vs $74.5M YoY; Napazimone FALCON Trial Enrollment Now Expected Complete In First Half 2027, 2026 Revenue Guidance Tightened To $380M-$390M From $375M-$395M Third quarter 2026 total revenues increase by 21% to approximately US$117.6 million, compared to third quarter 2025Third quarter 2026 total operating expenses of approximately US$74.6 million, in…
benzinga.com Pharming Says Leniolisib Reduced Spleen Volume In 10 Of 11 Evaluable Participants And Lymph Node Size In All 4 In Phase II Genetic PID Trial, With No New Safety Signals First clinical data for leniolisib in a larger group of PID participants beyond APDS, supporting the potential of targeted PI3Kδ inhibition to address immune dysregulationLeniolisib was…- benzinga.com HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and maintains $37 price target.
benzinga.com HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and maintains $37 price target.- benzinga.com Pharming Wins FDA Approval For Joenja In Children Ages 4 To 11 Who Weigh At Least 27kg, With New 40mg/50mg Twice-Daily Doses Expected In October FDA approval expands Joenja indication to include children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) ages 4 to 11 who weigh at least 27kgNewly approved Joenja doses are…
benzinga.com Pharming Launches Joenja (Leniolisib) in Japan for APDS Patients Aged 4 and Older, Marking First Global Launch for Children 4 To 11 Launch marks first commercial availability of Joenja® (leniolisib) for children aged 4 to 11 worldwideOrphanPacific, Inc. serves as Marketing Authorization holder and is responsible for supply and…
benzinga.com Canaccord Genuity Maintains Buy on Pharming, Raises Price Target to $38 Canaccord Genuity analyst Whitney Ijem maintains Pharming (NASDAQ:PHAR) with a Buy and raises the price target from $37 to $38.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Nuwellis (NASDAQ:NUWE) stock rose 119.0% to $4.14 during Thursday's pre-market session. GlucoTrack (NASDAQ:GCTK) stock increased by 47.36% to $0.42. The market value of their outstanding…
benzinga.com Meta Posts Mixed Q2 Results, Joins Coursera, Qualcomm And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. stock futures rise, Meta shares drop 9.4%, Teladoc Health and Rentokil Initial fall after mixed financial results.- benzinga.com Pharming Lowers FY2026 Sales Guidance from $405.000M-$425.000M to $375.000M-$395.000M vs $419.100M Est Pharming (NASDAQ:PHAR) lowers FY2026 sales outlook from $405.000 million-$425.000 million to $375.000 million-$395.000 million vs $419.100 million estimate.
- benzinga.com Pharming Q2 EPS $0.02, Inline, Sales $90.200M Miss $100.625M Estimate Pharming (NASDAQ:PHAR) reported quarterly earnings of $0.02 per share which met the analyst consensus estimate. This is a 66.67 percent decrease over earnings of $0.06 per share from the same period…
- benzinga.com Pharming Says FDA Accepts Joenja Application for Younger Children Pharming Group ((Euronext: PHARM, NASDAQ:PHAR) today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted supplemental New Drug Application (sNDA) seeking approval…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com Pharming Affirms FY2026 Sales Guidance of $405.000M-$425.000M vs $421.375M Est Pharming (NASDAQ:PHAR) affirms FY2026 sales outlook from $405.000 million-$425.000 million to $405.000 million-$425.000 million vs $421.375 million estimate.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Snap, Whirlpool, Nerdwallet And Other Big Stocks Moving Lower In Thursday's Pre-Market Session U.S. stock futures up, Dow futures gain 0.1% as Snap (NYSE: SNAP) shares fall 10.5%, Fastly (NASDAQ: FSLY) down 21.6%, and other stocks decline in pre-market trading.
benzinga.com Why Kulicke And Soffa Industries Shares Are Trading Higher By 19%; Here Are 20 Stocks Moving Premarket Shares of Kulicke & Soffa Industries (NASDAQ: VECO) rose after beating earnings estimates. Other gainers include Global Engine, Agilon Health, and Blue Bird Corp.- benzinga.com Pharming Projects FY2026 Total Revenues Of $405M-$425M With 8%-13% Growth Amid Pipeline Investments And Cost Reductions For 2026, the Company anticipates: Total revenues between US$405 million and US$425 million (8% to 13% growth), with quarterly fluctuations expected.Total operating expenses between US$330 million…
- benzinga.com Pharming Q1 EPS $(0.07) Misses $0.01 Estimate, Sales $72.400M Miss $93.750M Estimate Pharming (NASDAQ:PHAR) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $0.01 by 800 percent. This is a 68.18 percent increase over losses of $(0.22) per…
- benzinga.com Canaccord Genuity Initiates Coverage On Pharming with Buy Rating, Announces Price Target of $37 Canaccord Genuity analyst Whitney Ijem initiates coverage on Pharming (NASDAQ:PHAR) with a Buy rating and announces Price Target of $37.
- benzinga.com Pharming's Joenja Edges Closer To Becoming First EU-Approved APDS Treatment After Positive CHMP Opinion With European Commission Decision Due Q2 2026 If approved, Joenja® (leniolisib) would become the first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary…
benzinga.com HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and maintains $37 price target.
benzinga.com Earnings Scheduled For March 12, 2026 - benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Xpeng, Serina Therapeutics, Dragonfly Energy Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Why DarkIris Shares Are Trading Higher By Over 100%; Here Are 20 Stocks Moving Premarket 
benzinga.com Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Pharming Group Posts Upbeat Q3 Results, Joins On Holding, BigBear.ai Holdings And Other Big Stocks Moving Higher On Wednesday 
benzinga.com Earnings Scheduled For November 6, 2025 
benzinga.com Concentrix Posts Downbeat Earnings, Joins Legacy Education, Kingsoft Cloud And Other Big Stocks Moving Lower In Friday's Pre-Market Session U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Friday.
benzinga.com Why Top KingWin Shares Are Trading Higher By 87%; Here Are 20 Stocks Moving Premarket Shares of Top KingWin Ltd (NASDAQ: WAI) rose sharply in pre-market trading after the company announced it entered into a sales contract with Walker Times International for the sale of 10,000 units of…- benzinga.com Earnings Scheduled For July 31, 2025
- benzinga.com Earnings Scheduled For May 8, 2025
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com G-III Apparel Posts Better-Than-Expected Earnings, Joins Ballard Power Systems, Dollar General And Other Big Stocks Moving Higher On Thursday - benzinga.com Earnings Scheduled For March 13, 2025
- benzinga.com Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday